<DOC>
	<DOCNO>NCT01562275</DOCNO>
	<brief_summary>This open-label , multicenter , Phase Ib dose-escalation study evaluate safety , tolerability pharmacokinetics oral dose GDC-0973 GDC-0068 administered combination patient locally advance metastatic solid tumor . Cohorts patient receive multiple ascend dos GDC-0973 GDC-0068 . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Evaluating Safety , Tolerability , Pharmacokinetics GDC-0973 Combination With GDC-0068 When Administered Participants With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically cytologically document locally advanced metastatic solid tumor standard therapy either exist proven ineffective intolerable Evaluable disease disease measurable per Response Evaluation Criteria Solid Tumors ( RECIST ) Life expectancy &gt; /= 12 week Adequate hematologic end organ function History prior significant toxicity another MEK pathway inhibitor require discontinuation treatment History prior significant toxicity another phosphoinositide 3kinase ( PI3K ) Akt pathway mammalian target rapamycin ( mTOR ) inhibitor require discontinuation treatment Anticancer therapy within 28 day prior first dose study drug , except state protocol History type I type II diabetes mellitus require insulin Current severe , uncontrolled systemic disease ( e.g . clinically significant cardiovascular , pulmonary , metabolic disease ) Clinically significant history liver disease , current alcohol abuse , current know active infection HIV , hepatitis B hepatitis C virus Active autoimmune disease Pregnant lactate woman Known brain metastasis untreated , symptomatic , require therapy control symptoms History glaucoma History retinal vein occlusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>GDC0973</keyword>
	<keyword>MEK</keyword>
	<keyword>MEK inhibitor</keyword>
	<keyword>GDC0068</keyword>
	<keyword>Akt</keyword>
	<keyword>Akt inhibitor</keyword>
</DOC>